NICE publishes final draft guidance on nab-paclitaxel (Abraxane) for pancreatic cancer

21 Sep 2015
The National Institute for Health and Care Excellence (NICE)

The cost of using nab-paclitaxel (marketed as Abraxane by Celgene) to treat pancreatic cancer is not justified by its limited benefits compared to current treatments, according to NICE.

Please click here to read the 'The National Institute for Health and Care Excellence (NICE)' press release in full